Type 2 diabetes mellitus is a metabolic disease characterized by chronic hyperglycemia, which develops as a result of an increasing decrease in the production of insulin by pancreatic cells, and a violation of the interaction of insulin with tissue cells known as insulin resistance. The prevalence of chronic heart failure in patients with type 2 diabetes, as of December 2020, ranges from 24% to 40%.
According to the Health Care Cost Institute (HCCI), a nonprofit organization, in 2016, the annual cost of insulin for a patient with type 2 diabetes was $5,705, which is almost twice as high as in 2012 – $2,864. Some patients put their own health at risk and apply for payday loans New York to cover these obligations. The links will redirect you to the informative service where you may find as much information about payday loans Buffalo NY as possible.
In recent months, it has become common in the United States that diabetics have had to reduce the insulin dosage because of its high cost. In connection with the dissatisfaction of people in the country, protests were also held at the headquarters of a number of pharmaceutical companies.
According to the HCCI, the increase in insulin costs was primarily due to higher prices for insulin, as well as the transition of people with type 2 diabetes to more expensive insulin preparations. At the same time, the average daily insulin consumption increased from 2012 to 2016 by only 3%.
The drug makers say they need to periodically raise prices to offset the significant discounts they are offering to buyers under their health plans.
The current analysis looked at data from 15,000 patients with type 2 diabetes who were prescribed insulin at least once a year. As a result, it was found that from 2012 to 2016 the average price of insulin increased from 13 cents per unit to 25 cents. For the average patient using 60 units per day, the daily cost increased from $7.8 in 2012 to $15 in 2016.
To address this issue, the Democratic Party proposed legislation to reduce the cost of prescription drugs and sent letters to 12 manufacturers asking for information on price increases. The recipients of the message include the three largest insulin manufacturers – Eli Lilly & Co., Novo Nordisk A / S and Sanofi SA.
What is the stumbling block in the debate concerning the insulin price?
In May of this year, ten Democrats in the House of Representatives declared their opposition to the proposed law in a position that contradicted that of their own party. Most of them rely on financial support from large pharmaceutical companies, including Merck, Pfizer and Johnson & Johnson.
Swiss pharma companies, according to the CRP, of course also belong to this list. Scott Peters, a California congressman and one of the Democrats opposing the bill, received $7,500 in donations from Novartis and $7,000 from Roche for his 2020 re-election campaign.
Two other congressmen, Kurt Schrader and Tony Cardenas, from Oregon and California, received $8,500 and $5,000 from Roche last year, respectively. This shocking behavior led to the uncertainty of the future bill “On reducing the cost of drugs at the present time”, which means that the investment paid off. American patients will still have to wait a long time for the right drugs due to their soaring costs.